----item----
version: 1
id: {88ABB609-1950-4089-A119-939E6988AAF8}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/01/19/BMSs Andreotti steps down as CEO
parent: {BBA84A59-0029-4F55-ABF6-775540C65982}
name: BMSs Andreotti steps down as CEO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 5be53d9b-37c0-404d-965a-92793176226e

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 33

BMS's Andreotti steps down as CEO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

BMSs Andreotti steps down as CEO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1715

<p>Bristol-Myer's chief Lamberto Andreotti has announced his retirement as CEO of the company, effective 3 August 2015. He will be succeeded by current chief operating officer Dr Giovanni Caforio.</p><p>Mr Andreotti will remain at the company as executive chair of the board of directors, replacing James M Cornelius, who will not stand for re-election this year. Mr Andreotti joined Bristol-Myers Squibb in 1998 as vice-president and general manager, Italy and European oncology. He held a number of roles of increasing responsibility and was elected to the board of directors in March 2009 before becoming CEO in May 2010.</p><p>Meanwhile, Dr Caforio, BMS's current chief operating officer and past chief commercial officer, has been appointed as the company's new CEO. He has been a member of the BMS senior management team since 2011 and a member of the company's board since 2014. </p><p>Dr Caforio, speaking about his appointment, said: "I look forward to working with our very talented team of people at BMS to build on what we've accomplished, to deliver on the promise of our innovative portfolio and to continue to make a real difference for our patients."</p><p>BMS highlighted Dr Caforio's contributions to its immune-oncology strategy and integral role in shaping the company's successful transformation to a diversified specialty biopharma company. He first joined the company in 2000 as vice-president and general manager, Italy. He earned his MD from the University of Rome, prior to joining the pharmaceutical industry. He began his career in medical affairs at Abbott Laboratories. </p><p>BMS also announced that Togo D West has been named lead independent director on the company's board. </p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 200

<p>Bristol-Myer's chief Lamberto Andreotti has announced his retirement as CEO of the company, effective 3 August 2015. He will be succeeded by current chief operating officer Dr Giovanni Caforio.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

BMSs Andreotti steps down as CEO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150119T100000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150119T100000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150119T100000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027586
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 33

BMS's Andreotti steps down as CEO
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 4

news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356206
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042235Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

5be53d9b-37c0-404d-965a-92793176226e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042235Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
